Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab... скачать в хорошем качестве

Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab...

Dr Thierry Andre speaks to ecancer about the first results of nivolumab plus ipilimumab versus nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HWA. This is a phase three study that investigates treatment options for metastatic colorectal cancer patients with MSI or DMMR. It compares nivolumab plus ipilimumab against nivolumab alone, focusing on progression-free survival (PFS). Results show that combination therapy significantly improves PFS, with 71% of patients on the combination remaining progression-free at two years, compared to 56% on nivolumab alone. These findings suggest a potential new standard of care.